X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare SHASUN PHARMA with Cipla - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SHASUN PHARMA vs CIPLA - Comparison Results

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SHASUN PHARMA CIPLA SHASUN PHARMA/
CIPLA
 
P/E (TTM) x 123.9 37.6 329.7% View Chart
P/BV x 8.5 3.9 220.7% View Chart
Dividend Yield % 0.2 0.3 70.2%  

Financials

 SHASUN PHARMA   CIPLA
EQUITY SHARE DATA
    SHASUN PHARMA
Mar-14
CIPLA
Mar-17
SHASUN PHARMA/
CIPLA
5-Yr Chart
Click to enlarge
High Rs94622 15.1%   
Low Rs46458 9.9%   
Sales per share (Unadj.) Rs214.2181.9 117.8%  
Earnings per share (Unadj.) Rs5.312.9 41.5%  
Cash flow per share (Unadj.) Rs15.829.3 54.0%  
Dividends per share (Unadj.) Rs1.002.00 50.0%  
Dividend yield (eoy) %1.40.4 386.3%  
Book value per share (Unadj.) Rs53.3155.7 34.3%  
Shares outstanding (eoy) m56.62804.51 7.0%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x0.33.0 11.0%   
Avg P/E ratio x13.142.0 31.2%  
P/CF ratio (eoy) x4.418.4 24.0%  
Price / Book Value ratio x1.33.5 37.8%  
Dividend payout %18.715.5 120.6%   
Avg Mkt Cap Rs m3,958434,516 0.9%   
No. of employees `000NA23.0 0.0%   
Total wages/salary Rs m2,16426,338 8.2%   
Avg. sales/employee Rs ThNM6,349.1-  
Avg. wages/employee Rs ThNM1,143.0-  
Avg. net profit/employee Rs ThNM449.3-  
INCOME DATA
Net Sales Rs m12,127146,302 8.3%  
Other income Rs m2292,287 10.0%   
Total revenues Rs m12,356148,589 8.3%   
Gross profit Rs m1,00924,758 4.1%  
Depreciation Rs m59413,229 4.5%   
Interest Rs m4151,594 26.0%   
Profit before tax Rs m23012,222 1.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-70 0.4%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-731,798 -4.0%   
Profit after tax Rs m30210,354 2.9%  
Gross profit margin %8.316.9 49.2%  
Effective tax rate %-31.714.7 -215.2%   
Net profit margin %2.57.1 35.2%  
BALANCE SHEET DATA
Current assets Rs m6,88487,370 7.9%   
Current liabilities Rs m8,45633,081 25.6%   
Net working cap to sales %-13.037.1 -34.9%  
Current ratio x0.82.6 30.8%  
Inventory Days Days6287 70.9%  
Debtors Days Days10862 172.6%  
Net fixed assets Rs m4,970111,567 4.5%   
Share capital Rs m1131,609 7.0%   
"Free" reserves Rs m2,875123,645 2.3%   
Net worth Rs m3,020125,254 2.4%   
Long term debt Rs m1,81736,454 5.0%   
Total assets Rs m13,347209,532 6.4%  
Interest coverage x1.68.7 17.9%   
Debt to equity ratio x0.60.3 206.8%  
Sales to assets ratio x0.90.7 130.1%   
Return on assets %5.45.7 94.2%  
Return on equity %10.08.3 121.0%  
Return on capital %13.38.5 156.7%  
Exports to sales %46.434.2 135.5%   
Imports to sales %14.28.3 170.8%   
Exports (fob) Rs m5,62250,050 11.2%   
Imports (cif) Rs m1,72812,203 14.2%   
Fx inflow Rs m5,84351,066 11.4%   
Fx outflow Rs m2,17317,678 12.3%   
Net fx Rs m3,66933,388 11.0%   
CASH FLOW
From Operations Rs m39823,824 1.7%  
From Investments Rs m-1,635-13,127 12.5%  
From Financial Activity Rs m1,309-13,239 -9.9%  
Net Cashflow Rs m71-2,478 -2.9%  

Share Holding

Indian Promoters % 39.2 16.0 245.0%  
Foreign collaborators % 0.0 20.8 -  
Indian inst/Mut Fund % 3.6 12.2 29.5%  
FIIs % 17.6 23.7 74.3%  
ADR/GDR % 0.0 1.1 -  
Free float % 39.6 26.2 151.1%  
Shareholders   20,750 161,166 12.9%  
Pledged promoter(s) holding % 12.3 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SHASUN PHARMA With:   ALEMBIC PHARMA  FRESENIUS KABI ONCO.  GLENMARK PHARMA  ASTRAZENECA PHARMA  DISHMAN PHARMA  

Compare SHASUN PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 262 Points Lower; Metal & Realty Stocks Fall(Closing)

Indian share markets ended lower today amid weak global cues. At the closing bell, the BSE Sensex finished lower by 262 points.

Related Views on News

CIPLA Announces Quarterly Results (4QFY18); Net Profit Down 347.8%

May 24, 2018 | Updated on May 24, 2018

For the quarter ended March 2018, CIPLA has posted a net profit of Rs 2 bn (down 347.8% YoY). Sales on the other hand came in at Rs 37 bn (up 3.2% YoY). Read on for a complete analysis of CIPLA's quarterly results.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Cipla: Extraordinary Income Boosts Net Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

Proceeds from the sale of the South African animal business bolstered Cipla's net profits for the quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Should You Get out of Small Caps Now... Before the Fall Worsens(Profit Hunter)

Jun 6, 2018

An almost zero-loss strategy that works best when markets correct. Don't let the current volatility overwhelm you. Focus on the fundamentals and long term, and buy stocks where quality meets value.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SHASUN PHARMA SHARE PRICE


Nov 17, 2015 (Close)

TRACK SHASUN PHARMA

  • Track your investment in SHASUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SHASUN PHARMA - VENUS REMEDIES COMPARISON

COMPARE SHASUN PHARMA WITH

MARKET STATS